The DESTINY-Lung03 is a phase Ib study evaluating the safety of a combination of T-DXd with durvalumab (an anti–PD-L1 antibody) and platinum-based chemotherapy as first-line therapy in patients with advanced or metastatic ERBB2-mutated NSCLC [87]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.